Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04468997
Other study ID # 3SGJ601-AMD
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 12, 2018
Est. completion date September 15, 2021

Study information

Verified date July 2020
Source Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Contact Zhang Ming, Ph.D
Phone +86-028-85422452
Email zhangmingscu@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody


Description:

According to the results of preclinical pharmacological research and clinical application of bevacizumab in ophthalmology Case, 601 will be developed as a drug candidate for the treatment of ocular diseases such as wAMD .Observe the safety and tolerability of the single and multiple doses of 601 in wAMD patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple injections with different doses in the treatment of patients with wAMD.


Recruitment information / eligibility

Status Recruiting
Enrollment 67
Est. completion date September 15, 2021
Est. primary completion date March 15, 2021
Accepts healthy volunteers No
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria:

1. Sign informed consent form and willing to be visited at the time specified in the trial;

2. Age =45 years and age = 80 years;

3. The study eye must meet the following criteria:

- Diagnosis of wAMD;

- The presence of an primary or recurrent active choroidal neovascular (CNV) lesions in subfovea and para-fovea secondary to AMD;

- Total area of all types of lesions =30mm2 (12 optic disc areas)

- Best EDTRS letter score between 19 and 78(Snellen equivalent of 20/400 to 20/32);

- No optometric media opacity and pupil shrinkage.

4. Best EDTRS letter score =19 (Snellen equivalent of 20/400 or better) in the fellow eyes.

Exclusion Criteria:

Any of the following eye conditions:

1. Any eye has active ocular infections (e.g.,blepharitis, keratitis, scleritis, conjunctivitis);

2. History of vitreous hemorrhage in the study eye within 2 months before screening;

3. scarring, fibrosis, or atrophy below with fovea in the study eye;

4. Received any drug treatment for CNV within 120 days prior to screening;

5. History of any following surgery in the study eye (e.g. PDT, macular transposition, Glaucoma filtration, subfoveal photocoagulation, vitrectomy and transpupular hyperthermia, and other surgery at the submacular or others for AMD) within 3 months before screening;

6. CNV in the study eye associated with other ocular diseases such as pathologic myopia, eye trauma, etc

7. History or present of uncontrolled glaucoma, history of glaucoma filtering surgery in the study eye;

8. Subretinal hemorrhage in the study eye, and the bleeding area = 50% area of the total lesion;

9. History of rhegmatogenous retinal detachment or macular hole retinal detachment (stage 3 or 4) , retinal detachment, retinal pigment epithelium tear or macular area traction and macular area preretinal membrane and PCV in the study eye;

10. The study eye has no lens( except intraocular lens) or posterior capsular rupture of the lens;

Any of the following general condition are present:

11. Medicines with toxicity to the lens are being used or may be used during the study period;

12. History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis, history of allergy to more than two drugs and/or non-drug factors, or suffering from allergic diseases now.

13. History of surgery within 1 months before screening; and/or unhealed wounds, ulcers or fractures currently;

14. Suffering from systemic infections and requiring oral, intramuscular or intravenous medication;

15. History of stroke, myocardial infarction within 6 months before screening;

16. Active diffuse intravascular coagulation and obvious bleeding tendency within 3 months before screening;

17. Systemic immune diseases;

18. Uncontrolled blood pressure control ;

19. Diabetic patients with uncontrolled blood sugar;

20. Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumours);

Any of the following laboratory tests abnormalities(23-25):

21. Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory) Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory).

22. Abnormal coagulation function (prothrombin time >= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time >= the upper limit of normal value for 10 seconds);

Patients with childbearing age with any of the following conditions:

23. Those who do not use effective contraceptive measures;

The following are not excluded:

24. Pregnancy and lactation women (pregnancy is defined as urinary pregnancy test positive in this study);

Any other conditions:

25. Participation in any other drug clinical trials (except vitamins and minerals) in the past 1 month before screening ;

26. Researchers think it needs to be ruled out.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Drug 601
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
Drug 601
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
Drug 601
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
Drug 601
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
Drug 601
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
Drug 601
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.

Locations

Country Name City State
China BeiJing Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLT Incidence of dose-limiting toxicities up to the Day 14 visit From Day 0 up to Day 14
Primary MTD Maximum tolerated dose From Day 0 up to Day 56/112.
Secondary Pharmacokinetic (PK) profile Study the change of 601 drug concentration in the blood with time by mathematical principles and methods From Day 0 up to 56/112 days
Secondary Cmax The maximum blood concentration after 601 drug enters the bloodstream From Day 0 up to 56/112 days
Secondary t1/2 The half-life of drug 601, the time required for the terminal phase 601 drug concentration to drop by half From Day 0 up to 56/112 days
Secondary AUC Area under the concentration-time curve, reflect the characteristics of the exposure of 601 drug in the body. From Day 0 up to 56/112 days
Secondary Vd The proportional constant between the amount of 601 drug in the body and the blood concentration when the 601 drug achieves the dynamic balance in the body. From Day 0 up to 56/112 days
Secondary CL Clearance rate of drug 601 from the central ventricle. From Day 0 up to 56/112 days
Secondary MRT The average length of time that the 601 drug stays in the body. From Day 0 up to 56/112 days
Secondary ?z the ratio of the amount of elimination of 601 drug from the body per unit time to the total amount in the body From Day 0 up to 56/112 days
Secondary Biomarker Detection of VEGF concentration. From Day 0 up to 56/112 days
Secondary Immunogenicity Development of Anti-drug antibodies (ADA) after IVT injection of 601 From Day 0 up to 56/112 days
Secondary CRT Changes in central retina thickness (CRT) at all time points compared to the baseline From Day 0 up to 56/364 days
Secondary diseased region Changes in the diseased region at all time points compared to the baseline From Day 0 up to 56/364 days
See also
  Status Clinical Trial Phase
Completed NCT00138632 - Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Terminated NCT04594681 - A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration Phase 1
Completed NCT03585556 - AAVCAGsCD59 for the Treatment of Wet AMD Phase 1
Completed NCT03362190 - ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) Phase 2
Not yet recruiting NCT04564937 - The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD) Phase 1/Phase 2
Recruiting NCT04504123 - MMP-9 Inhibition for Recalcitrant Wet AMD Phase 2
Terminated NCT02005133 - A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics N/A
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Completed NCT03748784 - ADVM-022 Intravitreal Gene Therapy for Wet AMD Phase 1
Completed NCT04685369 - Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
Enrolling by invitation NCT04932980 - Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD N/A
Recruiting NCT05297292 - A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD Phase 2/Phase 3
Completed NCT03939767 - Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
Completed NCT03066258 - Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial Phase 1/Phase 2
Terminated NCT01086761 - Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration Phase 1
Recruiting NCT05727397 - Efficacy and Safety of RC28-E Versus Aflibercept Phase 3
Completed NCT04884399 - Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD Phase 1
Completed NCT04964089 - A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) Phase 3
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A
Terminated NCT00139282 - A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration Phase 3